3,3-dimethyl-1-methylsulfanyl-butane | 15672-93-2

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 3,3-dimethyl-1-methylsulfanyl-butane
• 英文别名: Methyl-<3,3-dimethyl-butyl>-sulfid；3,3-Dimethyl-1-methylsulfanylbutane
• CAS: 15672-93-2
• 化学式: C₇H₁₆S
• 分子量: 132.27
• InChiKey: KGKNTQSTLKJVGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3,3-dimethyl-1-methylsulfanyl-butane 在 methyl-methylene-sulfonium; hexachloroantimonate(1-) 作用下， 以 二氯甲烷 为溶剂， 生成 S-Chloro-3,3-dimethylbutyl-methylsulfoniumhexachloroantimonat
  参考文献：
  名称：

  The thioalkoxyalkylation of sulfides and other nucleophiles

  摘要：

  DOI：

  10.1016/s0040-4020(01)91633-3
• 作为产物：
  描述：

  3,3-二甲基-1-溴丁烷 [1647-23-0] 在 sodium methylate 作用下， 以 乙醇 为溶剂， 生成 3,3-dimethyl-1-methylsulfanyl-butane
  参考文献：
  名称：

  Banthorpe,D.V. et al., Journal of the Chemical Society, 1960, p. 4054 - 4087

  摘要：

  DOI：

文献信息

• Macrocyclic Modulators of the Ghrelin Receptor
  申请人：Ocera Therapeutics, Inc.

  公开号：US20180110824A1

  公开（公告）日：2018-04-26

  The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.

  本发明提供了一种新颖的构象定义明确的大环化合物，已经证明是生长激素分泌素受体（GHS-R1a及其亚型、异构体和变体）的选择性调节剂。本文还描述了合成这些新型化合物的方法。这些化合物可用作生长激素分泌素受体的激动剂，用于治疗和预防一系列医疗状况，包括但不限于代谢和/或内分泌紊乱、胃肠道紊乱、心血管疾病、肥胖和与肥胖相关的疾病、中枢神经系统疾病、遗传疾病、过度增殖性疾病和炎症性疾病。
• HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR
  申请人：AMGEN INC.

  公开号：US20170320860A1

  公开（公告）日：2017-11-09

  Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

  公式I和公式II的化合物，其药用盐，上述任何一个的立体异构体，或它们的混合物是APJ受体的激动剂，可能用于治疗心血管和其他疾病。公式I和公式II的化合物具有以下结构： 其中变量的定义在此提供。
• PROCESS FOR THE PREPARATION OF DIHYDROPYRROLE DERIVATIVES
  申请人：Syngenta Participations AG

  公开号：US20160073631A1

  公开（公告）日：2016-03-17

  The present invention provides stereoselective processes for the preparation of compounds of formula (I) wherein P is phenyl, naphthyl, a 6-membered heteroaryl group containing one or two nitrogen atoms as ring members, or a 10-membered bicyclic heteroaryl group containing one or two nitrogen atoms as ring members, and wherein the phenyl, naphthyl and heteroaryl groups are optionally substituted; R 1 is chlorodifluoromethyl or trifluoromethyl; R 2 is optionally substituted aryl or optionally substituted heteroaryl; n is 0 or 1; including the process comprising (a-i) reacting a compound of formula II wherein P, R 1 and R 2 are as defined for the compound of formula I; with nitromethane in the presence a chiral catalyst to give a compound of formula III wherein P, R 1 and R 2 are as defined for the compound of formula I; and (a-ii) reductively cyclising the compound of formula III to give the compound of formula I. The invention also provides intermediates useful for processes for the synthesis of compounds of formula (I).

  本发明提供了用于制备式(I)化合物的立体选择性过程，其中 P为苯基、萘基、含有一个或两个氮原子作为环成员的6元杂芳基，或含有一个或两个氮原子作为环成员的10元双环杂芳基，其中苯基、萘基和杂芳基可以选择性地被取代； R1为氯二氟甲基或三氟甲基； R2为可以选择性取代的芳基或可以选择性取代的杂芳基； n为0或1； 包括以下过程 (a-i)将式II化合物与硝基甲烷在手性催化剂存在下反应，得到式III化合物； 其中P、R1和R2如式I化合物中所定义； (a-ii)将式III化合物还原环化，得到式I化合物。 本发明还提供了用于合成式(I)化合物的过程的中间体。
• Diaryl piperidines as CB1 modulators
  申请人：Scott D. Jack

  公开号：US20070203183A1

  公开（公告）日：2007-08-30

  A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome (e.g., obesity, waist circumference, lipid profile, and insulin sensitivity), neuroinflammatory disorders, cognitive disorders, psychosis, addictive behavior, gastrointestinal disorders, and cardiovascular conditions.

  具有通式（I）的一种化合物，或其药学上可接受的盐、溶剂合物或酯，可用于治疗代谢综合征（例如肥胖、腰围、脂质谱和胰岛素敏感性）、神经炎症性疾病、认知障碍、精神病、成瘾行为、胃肠道疾病和心血管疾病等疾病、疾病或症状。
• SUBSTITUTED IMIDAZOLINE COMPOUNDS
  申请人：Merla Beatrix

  公开号：US20090048323A1

  公开（公告）日：2009-02-19

  Substituted imidazoline derivatives corresponding to Formula I: a method for producing them from substituted aldehyde compounds of Formula B: and the use of such imidazoline derivatives and aldehyde compounds to treat pain, depression, urinary incontinence, diarrhea, pruritus, alcohol and drug misuse, drug dependency, lethargy and/or anxiety.

  将对应于公式I的咪唑啉衍生物替代物：从公式B的替代醛化合物中生产它们的方法：以及使用这种咪唑啉衍生物和醛化合物来治疗疼痛、抑郁、尿失禁、腹泻、瘙痒、酒精和药物滥用、药物依赖、倦怠和/或焦虑。